ArticleAging2019
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Hypoxic microenvironment and pulmonary hypertension.Respiratory research · 2025Review
- Beneficial effects of magnesium nitrate on disease severity in male rats with monocrotaline-induced pulmonary hypertension.Physiological reports · 2025Article
- AFrontiers in cardiovascular medicine · 2024Article
- Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7.Frontiers in cardiovascular medicine · 2023Review
- Knockdown of TRPM7 attenuates apoptosis and inflammation in neonatal necrotizing enterocolitis model cell IEC-6 via modulating TLR4/NF-κB and MEK/ERK pathways.Iranian journal of basic medical sciences · 2022Article
- Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.Nature reviews. Cardiology · 2022Review
- Chemerin Regulates the Proliferation and Migration of Pulmonary Arterial Smooth Muscle CellsFrontiers in pharmacology · 2022Article
- Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension.Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2022Review
- From acute SARS-CoV-2 infection to pulmonary hypertension.Frontiers in physiology · 2022Review
- Mechanosensitivity in Pulmonary Circulation: Pathophysiological Relevance of Stretch-Activated Channels in Pulmonary Hypertension.Biomolecules · 2021Review
- Application of a novel haplotype-based scan for local adaptation to study high-altitude adaptation in rhesus macaques.Evolution letters · 2021Article
- Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on pulmonary hypertension.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure.Frontiers in physiology · 2021Review
- A bibliometric analysis and review of recent researches on TRPM7.Channels (Austin, Tex.) · 2020Review
- A Biodegradable Mg-Based Alloy Inhibited the Inflammatory Response of THP-1 Cell-Derived Macrophages Through the TRPM7-PI3K-AKT1 Signaling Axis.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased proliferation and apoptosis resistance of pulmonary artery smooth muscle cells (PASMCs) drive the progression of pulmonary arterial hypertension (PAH). The transient receptor potential melastatin 7 (TRPM7) is an endogenous magnesium channel reported to promote the proliferation of SMCs. However, whether TRPM7 is associated with PAH pathogenesis remains uncharacterized. We found that TRPM7 was downregulated in PASMCs from PAH human and Sprague-Dawley rats with hypoxia-induced PAH. Similar results were reproduced in PASMCs treated with PAH stimuli in vitro. Additionally, the TRPM7 currents and intracellular magnesium level in PASMCs were also reduced by PAH stimuli. Functionally, TRPM7 inhibition with waixenicin A or knockdown promoted, and reversely, its overexpression inhibited the proliferation and apoptosis resistance of PASMCs. Moreover, waixenicin A exacerbated hypoxia-induced PAH features in rats. Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH. In summary, these results may identify TRPM7 as a novel negative regulator in PAH pathogenesis, and suggest that improving its function may represent an antagonistic strategy to modify PAH progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.